Knocking out angiotensin II in the heart

Current Hypertension Reports

Volumn 13, Issue 2, 2011, Pages 129-135

  Zablocki, Daniela ^a   Sadoshima, Junichi ^a  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

Author keywords

ACE; ACE2; Angiotensin II; Cardiovascular disease; Chymase; Heart; RAS; Renin; Renin angiotensin system

Indexed keywords

ALISKIREN; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANGIOTENSIN CONVERTING ENZYME 2; ANGIOTENSIN DERIVATIVE; ANGIOTENSIN II; ANGIOTENSIN II [1-9]; ANGIOTENSIN II TYPE 1 RECEPTOR ASSOCIATED PROTEIN; ANGIOTENSIN[1-7]; ANTIHYPERTENSIVE AGENT; CELL PENETRATING PEPTIDE; CHYMASE; CYT006 ANGQB; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; PRORENIN; RENIN; RENIN INHIBITOR; UNCLASSIFIED DRUG;

ACUTE HEART INFARCTION; CARDIOVASCULAR DISEASE; CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; HEART FAILURE; HEART FUNCTION; HEART INFARCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART VENTRICLE HYPERTROPHY; HORMONE RECEPTOR INTERACTION; HUMAN; HYPERTENSION; NONHUMAN; PATHOPHYSIOLOGY; PROTEIN EXPRESSION; PROTEIN FUNCTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SIGNAL TRANSDUCTION; UNSPECIFIED SIDE EFFECT;

ANGIOTENSIN II; CHYMASES; HUMANS; MYOCARDIUM; PEPTIDYL-DIPEPTIDASE A; RENIN; RENIN-ANGIOTENSIN SYSTEM;

EID: 79955956184     PISSN: 15226417     EISSN: 15343111     Source Type: Journal    
DOI: 10.1007/s11906-011-0180-4     Document Type: Review

References (60)

1. Ferrario CM: New physiological concepts of the renin-angiotensin system from the investigation of precursors and products of angiotensin I metabolism. Hypertension 2010, 55(2):445-452.
2. Iusuf D, Henning RH, van Gilst WH, Roks AJ: Angiotensin-(1-7): pharmacological properties and pharmacotherapeutic perspectives. Eur J Pharmacol 2008, 585(2-3):303-312.
3. Kurdi M, De Mello WC, Booz GW: Working outside the system: an update on the unconventional behavior of the renin-angiotensin system components. Int J Biochem Cell Biol 2005, 37(7):1357-1367.
4. Re RN, Cook JL: The mitochondrial component of intracrine action. Am J Physiol 2010, 299(3):H577-583.
5. Schluter KD, Wenzel S: Angiotensin II: a hormone involved in and contributing to pro-hypertrophic cardiac networks and target of antihypertrophic cross-talks. Pharmacol Ther 2008, 119(3):311-325.
6. Burniston JG, Saini A, Tan LB, Goldspink DF: Angiotensin II induces apoptosis in vivo in skeletal, as well as cardiac, muscle of the rat. Exp Physiol 2005, 90(5):755-761. (Pubitemid 41406064)
7. Porrello ER, D'Amore A, Curl CL, et al.: Angiotensin II type 2 receptor antagonizes angiotensin II type 1 receptor-mediated cardiomyocyte autophagy. Hypertension 2009, 53(6):1032-1040. This study describes a previously unknown function of the RAS, providing the first evidence that Ang II and its receptors are involved in regulating autophagy in the heart.
8. Oyamada S, Bianchi C, Takai S, et al.: Impact of acute myocardial ischemia reperfusion on the tissue and blood-borne renin-angiotensin system. Basic Res Cardiol 2010, 105(4):513-522.
9. Peng H, Carretero OA, Liao TD, et al.: Role of N-acetyl-seryl-aspartyl- lysyl-proline in the antifibrotic and anti-inflammatory effects of the angiotensin-converting enzyme inhibitor captopril in hypertension. Hypertension 2007, 49(3):695-703.
10. Erdos EG, Tan F, Skidgel RA: Angiotensin I-converting enzyme inhibitors are allosteric enhancers of kinin B1 and B2 receptor function. Hypertension 2010, 55(2):214-220.
11. Miguel-Carrasco JL, Zambrano S, Blanca AJ, et al.: Captopril reduces cardiac inflammatory markers in spontaneously hypertensive rats by inactivation of NF-kB. J Inflamm 2010, 7:21.
12. Simko F, Pechanova O, Pelouch V, et al.: Effect of melatonin, captopril, spironolactone and simvastatin on blood pressure and left ventricular remodelling in spontaneously hypertensive rats. J Hypertens Suppl 2009, 27(6):S5-10.
13. Katragadda S, Arora RR: Role of angiotensin-converting enzyme inhibitors in vascular modulation: beyond the hypertensive effects. Am J Ther 2010, 17(1):e11-e23. This article is a good review of the data obtained from randomized controlled trials evaluating ACE inhibitors. However, it does not include the recent, much discussed ONTARGET study, which suggested that dual blockade with ACE inhibitors and ARBs may have little clinical benefit and may actually be detrimental in some patients.
14. Jessup M, Abraham WT, Casey DE, et al.: 2009 focused update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009, 119(14):1977-2016.
15. Kohlstedt K, Brandes RP, Muller-Esterl W, et al.: Angiotensin-converting enzyme is involved in outside-in signaling in endothelial cells. Circ Res 2004, 94(1):60-67. (Pubitemid 38064099)
16. Dell'Italia LJ, Husain A: Dissecting the role of chymase in angiotensin II formation and heart and blood vessel diseases. Curr Opin Cardiol 2002, 17(4):374-379. (Pubitemid 34864606)
17. Kumar R, Singh VP, Baker KM: The intracellular renin-angiotensin system in the heart. Curr Hypertens Rep 2009, 11 (2):104-110.
18. Miyazaki M, Takai S, Jin D, Muramatsu M: Pathological roles of angiotensin II produced by mast cell chymase and the effects of chymase inhibition in animal models. Pharmacol Ther 2006, 112 (3):668-676. (Pubitemid 44573489)
19. Wei CC, Hase N, Inoue Y, et al.: Mast cell chymase limits the cardiac efficacy of Ang I-converting enzyme inhibitor therapy in rodents. J Clin Invest 2010, 120(4):1229-1239. This study suggests that, rather than inhibiting local generation of Ang II, chronic ACE inhibition actually plays a direct role in maintaining Ang II levels in the cardiac interstitium by inducing chymasedependent Ang II synthesis.
20. Trask AJ, Jessup JA, Chappell MC, Ferrario CM: Angiotensin-(1-12) is an alternate substrate for angiotensin peptide production in the heart. Am J Physiol 2008, 294(5):H2242-2247. This study provides the first evidence that Ang-(1-12) can serve as an alternative precursor for Ang II synthesis.
21. Prosser HC, Forster ME, Richards AM, Pemberton CJ: Cardiac chymase converts rat proAngiotensin-12 (PA12) to angiotensin II: effects of PA12 upon cardiac haemodynamics. Cardiovasc Res 2009, 82(1):40-50.
22. Takai S, Jin D, Miyazaki M: New approaches to blockade of the renin-angiotensin-aldosterone system: chymase as an important target to prevent organ damage. J Pharmacol Sci 2010, 113 (4):301-309.
23. Singh VP, Le B, Khode R, et al.: Intracellular angiotensin II production in diabetic rats is correlated with cardiomyocyte apoptosis, oxidative stress, and cardiac fibrosis. Diabetes 2008, 57(12):3297-3306.
24. Wanka H, Kessler N, Ellmer J, et al.: Cytosolic renin is targeted to mitochondria and induces apoptosis in H9c2 rat cardiomyoblasts. J Cell Mol Med 2009, 13(9A):2926-2937.
25. Bispo-da-Silva LB, Sivieri-Jr DO, Prado CM, et al.: Cardiac mast cell proteases do not contribute to the regulation of the rat coronary vascular responsiveness to arterial delivered angiotensin I and II. Vascul Pharmacol 2010, 53(1-2):22-27.
26. Krop M, van Veghel R, Garrelds IM, et al.: Cardiac Renin levels are not influenced by the amount of resident mast cells. Hypertension 2009, 54(2):315-321.
27. Mackins CJ, Kano S, Seyedi N, et al.: Cardiac mast cell-derived renin promotes local angiotensin formation, norepinephrine release, and arrhythmias in ischemia/reperfusion. J Clin Invest 2006, 116(4):1063-1070.
28. Israili ZH, Velasco M, Bermudez V: Direct renin inhibitors as antihypertensive agents. Am J Ther 2010, 17(3):237-254. This review article gives a good overview of the function and effectiveness of currently available direct renin inhibitors.
29. van Esch JH, Moltzer E, van Veghel R, et al.: Beneficial cardiac effects of the renin inhibitor aliskiren in spontaneously hypertensive rats. J Hypertens 2010, 28(10):2145-2155.
30. McMurray JJ, Pitt B, Latini R, et al.: Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure. Circ Heart Fail 2008, 1(1):17-24.
31. Solomon SD, Appelbaum E, Manning WJ, et al.: Effect of the direct Renin inhibitor aliskiren, the Angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy. Circulation 2009, 119(4):530-537.
32. Feldt S, Batenburg WW, Mazak I, et al.: Prorenin and renin-induced extracellular signal-regulated kinase 1/2 activation in monocytes is not blocked by aliskiren or the handle-region peptide. Hypertension 2008, 51(3):682-688. This study provides evidence that binding of renin or prorenin to the (pro)renin receptor can trigger Ang II-independent cellular signaling that is not blocked by renin inhibition.
33. Ferrario CM, Varagic J, Habibi J, et al.: Differential regulation of angiotensin-(1-12) in plasma and cardiac tissue in response to bilateral nephrectomy. Am J Physiol 2009, 296(4):H1184-1192.
34. Tadevosyan A, Maguy A, Villeneuve LR, et al.: Nuclear-delimited angiotensin receptor-mediated signaling regulates cardiomyocyte gene expression. J Biol Chem 2010, 285(29):22338-22349.
35. Steckelings UM, Kaschina E, Unger T: The AT2 receptor - a matter of love and hate. Peptides 2005, 26(8):1401-1409. (Pubitemid 41021474)
36. Weber M: Achieving blood pressure goals: should angiotensin II receptor blockers become first-line treatment in hypertension? J Hypertens Suppl 2009, 27(5):S9-14.
37. Siragy HM: Comparing angiotensin II receptor blockers on benefits beyond blood pressure. Adv Ther 2010, 27(5):257-284. This article is a good review of clinical data on the effectiveness of ARBs in treating cardiovascular diseases.
38. Konstam MA, Neaton JD, Dickstein K, et al.: Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial. Lancet 2009, 374(9704):1840-1848.
39. Miura SI, Karnik SS, Saku K: Angiotensin II type 1 receptor blockers: class effects versus molecular effects. J Renin Angiotensin Aldosterone Syst 2010.
40. Sadoshima J: Novel AT(1) receptor-independent functions of losartan. Circ Res 2002, 90(7):754-756.
41. Sipahi I, Debanne SM, Rowland DY, et al.: Angiotensin-receptor blockade and risk of cancer: meta-analysis of randomised controlled trials. Lancet Oncol 2010, 11(7):627-636. In this meta-analysis, Sipahi et al. suggest that ARB use may be associated with an increased risk of cancer.
42. Tamura K, Tanaka Y, Tsurumi Y, et al.: The role of angiotensin AT1 receptor-associated protein in renin-angiotensin system regulation and function. Curr Hypertens Rep 2007, 9(2):121-127. (Pubitemid 46779376)
43. Wakui H, Tamura K, Tanaka Y, et al.: Cardiac-specific activation of angiotensin II type 1 receptor-associated protein completely suppresses cardiac hypertrophy in chronic angiotensin II-infused mice. Hypertension 2010, 55(5):1157-1164. This transgenic mouse study provides evidence that the endogenous AT1R inhibitor, ATRAP, may be an effective way to suppress Ang II-induced cardiac hypertrophy.
44. Yu J, Taylor L, Mierke D, et al.: Limiting angiotensin II signaling with a cell-penetrating peptide mimicking the second intracellular loop of the angiotensin II type-I receptor. Chem Biol Drug Des 2010, 76(1):70-76.
45. Yayama K, Okamoto H: Angiotensin II-induced vasodilation via type 2 receptor: role of bradykinin and nitric oxide. Int Immunopharmacol 2008, 8(2):312-318.
46. Moltzer E, Verkuil AV, van Veghel R, et al.: Effects of angiotensin metabolites in the coronary vascular bed of the spontaneously hypertensive rat: loss of angiotensin II type 2 receptor-mediated vasodilation. Hypertension 2010, 55(2):516-522. This study provides evidence that AT2R function may switch from relaxant to constrictor under hypertensive conditions, suggesting that further investigation of its signaling mechanisms is required to better understand what effects AT2R agonists may have in a clinical setting.
47. Kaschina E, Grzesiak A, Li J, et al.: Angiotensin II type 2 receptor stimulation: a novel option of therapeutic interference with the renin-angiotensin system in myocardial infarction? Circulation 2008, 118(24):2523-2532.
48. Gurley SB, Coffman TM: Angiotensin-converting enzyme 2 gene targeting studies in mice: mixed messages. Exp Physiol 2008, 93 (5):538-542. (Pubitemid 351595062)
49. Der Sarkissian S, Grobe JL, Yuan L, et al.: Cardiac overexpression of angiotensin converting enzyme 2 protects the heart from ischemia-induced pathophysiology. Hypertension 2008, 51 (3):712-718. (Pubitemid 351301525)
50. Kassiri Z, Zhong J, Guo D, et al.: Loss of angiotensin-converting enzyme 2 accelerates maladaptive left ventricular remodeling in response to myocardial infarction. Circ Heart Fail 2009, 2(5):446-455.
51. Trask AJ, Groban L, Westwood BM, et al.: Inhibition of angiotensin-converting enzyme 2 exacerbates cardiac hypertrophy and fibrosis in Ren-2 hypertensive rats. Am J Hypertens 2010, 23 (6):687-693.
52. Zhong J, Basu R, Guo D, et al.: Angiotensin-converting enzyme 2 suppresses pathological hypertrophy, myocardial fibrosis, and cardiac dysfunction. Circulation 2010, 122(7):717-728, 718 p following 728.
53. Ferreira AJ, Santos RA, Bradford CN, et al.: Therapeutic implications of the vasoprotective axis of the renin-angiotensin system in cardiovascular diseases. Hypertension 2010, 55(2):207-213.
54. Mercure C, Yogi A, Callera GE, et al.: Angiotensin(1-7) blunts hypertensive cardiac remodeling by a direct effect on the heart. Circ Res 2008, 103(11):1319-1326. This study suggests that the beneficial effects of ACE2 activity in the heart may be due in part to the resultant increase in Ang-(1-7) levels, rather than simply the degradation of Ang II.
55. Wang Y, Qian C, Roks AJ, et al.: Circulating rather than cardiac angiotensin-(1-7) stimulates cardioprotection after myocardial infarction. Circ Heart Fail 2010, 3(2):286-293.
56. Ocaranza MP, Lavandero S, Jalil JE, et al.: Angiotensin-(1-9) regulates cardiac hypertrophy in vivo and in vitro. J Hypertens 2010, 28(5):1054-1064. This study is the first to demonstrate a role for Ang-(1-9) in the regulation of cardiac hypertrophy.
57. Masson R, Nicklin SA, Craig MA, et al.: Onset of experimental severe cardiac fibrosis is mediated by overexpression of Angiotensin-converting enzyme 2. Hypertension 2009, 53 (4):694-700.
58. Lambert DW, Clarke NE, Turner AJ: Not just angiotensinases: new roles for the angiotensin-converting enzymes. Cell Mol Life Sci 2010, 67(1):89-98.
59. Maurer P, Bachmann MF: Immunization against angiotensins for the treatment of hypertension. Clin Immunol 2010, 134(1):89-95.
60. Petrov VI, Nedogoda SV, Epshtein OI, et al.: The use of ultralow doses of antibodies to C-terminal fragment of angiotensin II AT1 receptor (kardos) in the therapy of arterial hypertension. Bull Exp Biol Med 2009, 148(2):332-334.